ClickCease

Merrimack Pharmaceuticals Inc. (Nasdaq: MACK) Gaps up – Comes Down

Merrimack Pharmaceuticals, Inc. – Nasdaq: MACK

Heavy social media chatter focused on Merrimack Pharmaceuticals this morning. Mack, traded on the Nasdaq, shares were sent higher ($5.61) before settling back into the high range of the $3 handle. MACK closed Friday at $3.60.

The Cambridge, MA-based biotechnology firm had announced agreement to sell its Onivide and generic version of Doxil to Ipsen for a reported $1.025 Billion. $200 million of the proceeds would be used as a special cash dividend to shareholders of MACK.

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error.

Three firms follow Merrimack Pharmaceuticals. All three give MACK a “Hold” rating. Their consensus price target is $7.00. Reported EPS for MACK has never been positive and last year was the largest EPS loss for Merrimack at -$1.33. Sales have fared better with Merrimack reporting a high-water marke last year of $102 million but only $89.3 million in 2015.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/9/2017
Ticker Symbol MACK
Last Price a/o 10:00 AM EST  $                      4.07
Average Volume 3.2 million
Market Cap $492 million
Sales $104.5 million
Shares Outstanding 136.8 million
Share Float 122.4 million
Shortable Yes
Optionable Yes
Inside Ownership 0.10%
Short Float 30.74%
Short Interest Ratio 11.73
Quarterly Return -39.80%
YTD Return -11.76%
Year Return -45.78%

Genocea Biosciences Inc. (Nasdaq: GNCA) Reports Phase 2b results – shares up

Genocea Biosciences, Inc. – Nasdaq: GNCA

Genocea Biosciences Inc. reported positive results in a Phase 2b clinical trial. Shares (Nasdaq: GNCa) are up over 13% on the news.

Chip Clark, president and chief executive officer of Genocea stated “We are very pleased to have demonstrated such a powerful impact on genital herpes clinical disease in this trial, supporting the groundbreaking potential of GEN-003 to be the first-ever therapeutic vaccine for a chronic infection and the first advance in the treatment of genital herpes in more than 20 years…”

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs.

Five firms follow Gencocea Biosciences Inc. Four rate GNCA as a “Strong Buy” and one rates GNCA a “Buy”. Their consensus pricet target is $15. Genocea Bioscinces reported sales of $700,000 in 2015. This represented a drop from their 2012 reported sales of $2 million. EPS for GNCA have a similar history. Never achieving positive EPS, GNCA had its worst reporting year in 2014 when they lost $2.27 EPS. In 2015 GNCA improved to a loss of $$1,74 EPS.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/5/17
Ticker Symbol GNCA
Last Price a/o 8:50 AM EST $5.15
Average Volume 132,000
Market Cap $130.4 million
Sales 0.50 million
Shares Outstanding 28.74 million
Share Float 24.8 million
Shortable Yes
Optionable Yes
Inside Ownership 0.40%
Short Float 14.15%
Short Interest Ratio 16.56
Quarterly Return 1.79%
YTD Return 10.19%
Year Return -10.63%

Halozyme Therapeutics, Inc. (Nasdaq: HALO) Reports Phase 2 Results – Shares Near 52-Week High

Halozyme Therapeutics, Inc. – Nasdaq: HALO

Shares of Halozyme Therapeutics, Inc. traded near their 52-week highs in this morning’s pre-market action. Shares are traded on the Nasdaq under the ticker HALO. HALO’s 52- week high was $17.19 and this morning shares rocketed nearly 60% to a pre-market high of $17.00. Traders are responding to favorable results in HaloZyme Therapeutics’ Phase 2 trial addressing cancer of the Pancreas. Pancreatic cancer is the third-leading cause of cancer related death in the United States, and more than 65,000 people in the U.S. and top five European countries are diagnosed annually with advanced cases of the disease.

San Diego, CA-based Halozyme Therapeutics, Inc. reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO 202 study in stage IV pancreas cancer patients. Among the findings, the overall study population showed a statistically significant increase in progression-free survival in patients with high levels of hyaluronan (HA-High) treated with PEGPH20 plus Abraxane and gemcitabine when compared to HA-High patients receiving Abraxane and gemcitabine alone. Stage 2 of the study, which completed enrollment in February 2016, showed a 91 percent improvement in median PFS for HA-High patients in the PEGPH20 arm, 8.6 months compared to 4.5 months in the control arm, and achieved its primary endpoint.

Halozyme Therapeutics Inc. reported sales of $135.1 million in 2015 – an improvement from reported 2012 sales of $42.3 million. EPS for HALO has had similar improvement, losing $0.74 in 2013 but only losing $0.25 in 2015.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/5/17
Ticker Symbol HALO
Last Price a/o 7:31 AM EST $17.05
Average Volume 1.6 million
Market Cap $1.39 Billion
Sales $160 million
Shares Outstanding 130,27 million
Share Float 108.71 million
Shortable Yes
Optionable Yes
Inside Ownership 0.10%
Short Float 20.06%
Short Interest Ratio 13.68
Quarterly Return -9.87%
YTD Return 8.20%
Year Return -34.78%